A 5.1-month improvement in median progression-free survival — from 6.4 months on pembrolizumab monotherapy to 11.5 months on high-dose fianlimab plus cemiplimab — was not enough. That delta, clinically meaningful by almost any conventional standard, failed to cross the threshold of statistical significance, landing at a hazard ratio of 0.845 with a p-value of 0.0627. In a 1,546-patient trial with four arms and two dose levels, Regeneron’s LAG-3 inhibitor program in first-line metastatic melanoma has hit a wall it cannot easily explain away.
The design itself deserves scrutiny. Testing two dose levels simultaneously — 1600 mg and 400 mg fianlimab, each paired with 350 mg cemiplimab — against pembrolizumab monotherapy created a statistical burden the trial was never going to carry lightly. The low-dose arm performed worse, with a hazard ratio of 0.931 and a p-value of 0.4661, essentially indistinguishable from the control. Including a cemiplimab monotherapy arm (n=154) as a component-contribution reference was scientifically reasonable but added complexity without adding power where it mattered. The trial was designed to answer multiple questions at once and ended up answering none of them definitively.
The LAG-3 class is not dead — Bristol Myers Squibb’s Opdualag already holds FDA approval in this same indication, and that approval is precisely why the ongoing head-to-head trial matters more than this result does. Regeneron has positioned the high-dose combination directly against Opdualag in a separate Phase 3, and the fianlimab-cemiplimab pairing still has a theoretical immunological argument: dual checkpoint blockade via PD-1 and LAG-3 operating through two distinct antibody constructs rather than a fixed-dose combination. Whether that mechanistic flexibility translates into superior outcomes is now the entire question.
The number to watch is the hazard ratio from the head-to-head Opdualag comparison. Opdualag’s own approval rested on a PFS hazard ratio of 0.75 versus nivolumab monotherapy. If fianlimab plus cemiplimab cannot beat that benchmark against a LAG-3 combination rather than a PD-1 monotherapy, the program’s first-line melanoma ambitions are effectively finished — regardless of how the median PFS numbers look in isolation.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
